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Abstract
To assess the impact of COVID‐19 restrictions on cystic fibrosis (CF) pulmonary
exacerbations (PEx) we performed a retrospective review of PEx events at our CF
Center and compared the rate of PEx in 2019 versus 2020. Restrictions on social
interaction due to the COVID‐19 pandemic were associated with a lower number of
PEx events at our pediatric CF Center, suggesting that these restrictions also
reduced exposure to other respiratory viral infection in children with CF.
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To The Editor,
The COVID‐19 pandemic resulted in widespread restrictions on so-
cial interactions and lockdowns in many areas of the world.1 The
impact of these measures on cystic fibrosis (CF) pulmonary exacer-
bations (PEx) has not been described. Respiratory viral infections are
a common trigger for PEx,2,3 and COVID‐19 restrictions might lead
to fewer PEx by reducing exposure to viruses in general, not just
SARS‐CoV2. To test the hypothesis that the COVID‐19 lockdown
would be associated with a lower PEx incidence we compared PEx
data at our CF Center from the time with the most stringent re-
strictions in Indiana to the same time interval in 2019.
We identified PEx events by performing a retrospective chart
review of children with CF followed at the CF Center at Riley Hos-
pital for Children. We limited the lower age range to 2 years because
differentiating viral upper respiratory infection from PEx can be
difficult in this age group,4 and we set an upper age limit of 11 years
to avoid any potential confounding by elexacaftor/tezacaftor/iva-
caftor therapy.5,6 The first COVID‐19 case in Indiana was reported
on March 1, and the peak incidence of infection during the Spring
occurred on April 23. A statewide lockdown was initiated on March
23. With this timeline in mind, we collected data from two time
intervals in both 2019 and 2020: January 1–March 15 (which cor-
responded to the months before the COVID‐19 detection in Indiana)
and March 16–May 15 (which corresponded with the months of peak
COVID‐19 incidence in the Spring of 2020). PEx was determined by
the treating clinician based on changes in signs, symptoms, and/or
lung function that led to oral or intravenous antibiotic therapy. Every
PEx event was analyzed during these timeframes, and data collected
included demographics, height and weight, lung function, micro-
biology, location of encounter, and antibiotic treatment. Testing for
respiratory viruses is not part of our routine clinical care and data on
viral testing was not available for analysis. Data were analyzed using
descriptive statistics and generalized linear models where data had
repeated measures. This project was reviewed and approved by our
local institutional review board before data collection.
The number and location of PEx events during the time intervals
studies are shown in the Table 1. The number of PEx events were
significantly decreased in both time intervals in 2020 compared to
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2019, although the decline was even greater from March 16 to
May 15. The location of patients' PEx events also differed between
2019 and 2020, with a significantly lower percentage of PEx iden-
tified through in‐person clinic visits and a much larger percentage
identified through phone encounters. The number of patients (80 in
2019 and 78 in 2020) and their clinical characteristics, such as sex,
genotype, respiratory culture history, baseline lung function, and
nutritional indices were similar for both years, suggesting that our
observations were not due to an overall improvement in the health
of our patients. However, whereas 100% of clinic visits in 2019 and
from January 1 to March 16 2020 were in‐person, only 16% of visits
during the March 16–May 15, 2020 time interval were in‐person.
Our analysis shows that COVID‐19 restrictions were associated
with decreased PEx events and a shift towards PEx diagnosis through
phone encounters rather than in‐person visits. We speculate that this
may have occurred due to reduced exposure to respiratory viral in-
fections in general. Reports have demonstrated sharply decreased in-
fluenza and RSV activity associated with lockdowns.7,8 It is also
possible that because our patients and their parents were both at
home more, there was improved adherence. Alternatively, it is possible
that PEx were missed due to a reduction in measurements of lung
function. However, we observed a reduction in PEx reported via phone
encounters, which would not have been affected by the reduction in
lung function measurements. Furthermore, we also observed a re-
duction in PEx rate before March 16, which may reflect the fact that
patients were already engaging in a degree of self‐isolation before the
statewide lockdown. The decrease in in‐person PEx events reflects the
increased use of telehealth at the height of the COVID‐19 pandemic in
Indiana. Limitations of our analysis include the retrospective study
design and the fact that we only analyzed data from a single CF Center.
Another limitation is that we did not have a standardized definition of
PEx and PEx status was not always explicitly documented in the
medical record. We, therefore, inferred PEx status by the patient's
clinical signs and symptoms, lung function data (when available), and
the clinician's decision to use antibiotic therapy.
In summary, restrictions on social interaction due to the COVID‐19
pandemic were associated with a lower rate of PEx at our pediatric CF
Center. These results are consistent with other studies demonstrating
the importance of respiratory viral infections as a trigger for PEx and will
help CF clinicians anticipate the burden of CF lung disease should severe
lockdowns due to COVID‐19 occur again in their region.
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